{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:18:54Z","timestamp":1778073534709,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Private Universit\u00e4t Witten\/Herdecke gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Venovenous extracorporeal membrane oxygenation (VV-ECMO) is a mechanical life support modality used in patients with severe respiratory failure. Despite rising case numbers worldwide, costs are substantial, while patient-centered outcomes, particularly survival and quality-adjusted life years (QALYs), remain uncertain. High complication and mortality rates also persist. Limited financial budgets, human resources, and treatment capacities in healthcare systems require critical evaluation of whether continued use of this resource-intensive intervention at the current scale is sustainable and ethically justifiable. This study aims to provide further insight into this issue and to support healthcare decision-making by offering a structured economic and ethical framework for evaluating VV-ECMO, particularly regarding resource allocation, proportionality of costs, and the justification of its use in high-cost intensive care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This mixed-methods study consists of two parts. Part A includes two systematic literature reviews. The first examines total and daily in-hospital costs per patient, as well as outcomes measured in QALYs for adult patients supported with VV-ECMO across multiple countries between 2005 and 2024. The second aim is to identify established interventions with confirmed QALY gain that can subsequently be used as comparators for VV-ECMO. Part B evaluates the results according to the principles of medical ethics: beneficence, non-maleficence, autonomy, and justice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Given limited financial, personnel, and treatment capacities in healthcare systems, the question of how highly resource-intensive interventions such as VV-ECMO can be justified has increasing clinical, economic, and ethical relevance. By linking cost-related outcomes with a structured ethical evaluation, this study aims to contribute to a more differentiated discussion of whether and under which conditions VV-ECMO may be considered proportionate and justifiable within resource-constrained healthcare settings. Expected challenges include data availability and quality, differences in reported charges versus costs, and variation in healthcare systems, reimbursement structures, and national decision-making frameworks. These factors represent inherent limitations of international comparisons. The analysis is therefore intended as a comparative and contextual assessment rather than a formal cost-effectiveness evaluation within a single national reimbursement framework, particularly as no officially established uniform willingness-to-pay threshold per QALY exists in Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      Not applicable. This study does not involve interventional clinical research. The protocol was registered on the Open Science Framework (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/osf.io\/24ky5\" ext-link-type=\"uri\">https:\/\/osf.io\/24ky5<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12962-026-00755-8","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:36:49Z","timestamp":1778071009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Costs of venovenous extracorporeal membrane oxygenation (VV-ECMO) and its potential contribution to quality-adjusted life years: a mixed-methods study protocol"],"prefix":"10.1186","volume":"24","author":[{"given":"Marisa","family":"Haupert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Burisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timur","family":"Sellmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"9698","key":"755_CR1","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0140-6736(09)61069-2","volume":"374","author":"GJ Peek","year":"2009","unstructured":"Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009;374(9698):1351\u201363.","journal-title":"Lancet"},{"issue":"12","key":"755_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJM197203232861204","volume":"286","author":"JD Hill","year":"1972","unstructured":"Hill JD, O\u2019Brien TG, Murray JJ, Dontigny L, Bramson ML, Osborn JJ, et al. Prolonged Extracorporeal Oxygenation for Acute Post-Traumatic Respiratory Failure (Shock-Lung Syndrome): Use of the Bramson Membrane Lung. N Engl J Med. 1972;286(12):629\u201334.","journal-title":"N Engl J Med"},{"issue":"21","key":"755_CR3","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1056\/NEJMoa1800385","volume":"378","author":"A Combes","year":"2018","unstructured":"Combes A, Hajage D, Capellier G, Demoule A, Lavoue S, Guervilly C, et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. N Engl J Med. 2018;378(21):1965\u201375.","journal-title":"N Engl J Med"},{"issue":"2","key":"755_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/MAT.0000000000002128","volume":"70","author":"JE Tonna","year":"2024","unstructured":"Tonna JE, Boonstra PS, MacLaren G, Paden M, Brodie D, Anders M, et al. Extracorporeal Life Support Organization Registry International Report 2022: 100,000 Survivors. ASAIO J. 2024;70(2):131\u201343.","journal-title":"ASAIO J"},{"issue":"1","key":"755_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13054-021-03463-2","volume":"25","author":"B Friedrichson","year":"2021","unstructured":"Friedrichson B, Mutlak H, Zacharowski K, Piekarski F. Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs. Crit Care. 2021;25(1):38.","journal-title":"Crit Care"},{"issue":"1","key":"755_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/MAT.0000000000000160","volume":"61","author":"CM Sauer","year":"2015","unstructured":"Sauer CM, Yuh DD, Bonde P. Extracorporeal membrane oxygenation use has increased by 433% in adults in the United States from 2006 to 2011. ASAIO J. 2015;61(1):31\u20136.","journal-title":"ASAIO J"},{"issue":"1","key":"755_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s13054-021-03831-y","volume":"25","author":"C Karagiannidis","year":"2021","unstructured":"Karagiannidis C, Slutsky AS, Bein T, Windisch W, Weber-Carstens S, Brodie D. Complete countrywide mortality in COVID patients receiving ECMO in Germany throughout the first three waves of the pandemic. Crit Care. 2021;25(1):413.","journal-title":"Crit Care"},{"issue":"4","key":"755_CR8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s41669-021-00272-9","volume":"5","author":"A Oude Lansink-Hartgring","year":"2021","unstructured":"Oude Lansink-Hartgring A, van Minnen O, Vermeulen KM, van den Bergh WM. Hospital Costs of Extracorporeal Membrane Oxygenation in Adults: A Systematic Review. Pharmacoecon Open. 2021;5(4):613\u201323.","journal-title":"Pharmacoecon Open"},{"key":"755_CR9","unstructured":"\u00c4rzteZeitung. So viel kostet eine station\u00e4re COVID-19 Behandlung 2022 [cited 2025 Jun 18]. Available from: https:\/\/www.aerztezeitung.de\/Politik\/So-viel-kostet-ein-stationaer-behandelter-COVID-19-Patienten-die-Krankenkassen-425842.html"},{"issue":"5","key":"755_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1177\/02676591211005697","volume":"37","author":"A Dhamija","year":"2022","unstructured":"Dhamija A, Thibault D, Fugett J, Hayanga HK, McCarthy P, Badhwar V, et al. Incremental effect of complications on mortality and hospital costs in adult ECMO patients. Perfusion. 2022;37(5):461\u20139.","journal-title":"Perfusion"},{"issue":"Suppl 1","key":"755_CR11","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1111\/j.1524-4733.2009.00515.x","volume":"12","author":"MC Weinstein","year":"2009","unstructured":"Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health. 2009;12(Suppl 1):S5\u20139.","journal-title":"Value Health"},{"key":"755_CR12","unstructured":"Beauchamp TL, Childress JF. Principles of biomedical ethics. 8th ed. New York, Oxford: Oxford University Press; 2019. xvi, 496 p."},{"key":"755_CR13","doi-asserted-by":"crossref","unstructured":"Machlaurin A, Dolk FCK, Setiawan D, van der Werf TS, Postma MJ. Cost-Effectiveness Analysis of BCG Vaccination against Tuberculosis in Indonesia: A Model-Based Study. Vaccines (Basel). 2020;8(4).","DOI":"10.3390\/vaccines8040707"},{"key":"755_CR14","unstructured":"Agency CsD. Canada\u2019s Drug Agency Search Filters Database Ottawa: Canada\u2019s Drug Agency; 2025 [cited 2025 11 June]. Available from: https:\/\/searchfilters.cda-amc.ca"},{"key":"755_CR15","unstructured":"Statistisches Bundesamt. Statistisches Bundesamt Wiesbaden Statistisches Bundesamt 2025 [cited 2025 18 June]. Available from: https:\/\/www.destatis.de\/DE\/Home\/_inhalt.html"},{"key":"755_CR16","unstructured":"GKV-Spitzenverband. GKV-Spitzenverband Berlin2025 [cited 2025 18 June]. Available from: https:\/\/www.gkv-spitzenverband.de"},{"key":"755_CR17","unstructured":"Verband der privaten Krankenversicherung e.V. PKV \u2013 Private Krankenversicherung K\u00f6ln: PKV-Verband 2025 [cited 2025 18 June]. Available from: https:\/\/www.pkv.de"},{"key":"755_CR18","unstructured":"Wissenschaftliches Institut der AOK (WIdo). WIdO - Wissenschaftliches Institut der AOK Berlin WIdo. 2025 [cited 2025 18 June]. Available from: https:\/\/www.wido.de"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-026-00755-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00755-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00755-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:56:42Z","timestamp":1778072202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-026-00755-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["755"],"URL":"https:\/\/doi.org\/10.1186\/s12962-026-00755-8","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Ethics Committee of the University Witten\/Herdecke (reference number: S-136\/2025). This study is conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"Not applicable. This study is based exclusively on secondary data analysis and published literature. It does not involve direct patient contact.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}